News

GSK, Pfizer and CureVac

CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight against COVID-19.
Pfizer, BioNTech reach Covid jab settlement with GSK, CureVac
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 million
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
CureVac (NASDAQ:CVAC) announced on Friday that the company and its partner, GSK (NYSE:GSK), are set to receive $740M and other payments, as Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have agreed to resolve a patent dispute related to messenger-RNA-based COVID vaccines in the U.
BioNTech settles Covid-19 patent dispute with CureVac
BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the purchase of its German rival.
GSK to Receive $370 Million in U.S. Patent Litigation Settlement
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.
GSK to be paid up to £370 million after patent row settles in US
CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.
Malay Mail8h

Covid vaccine patent fight finally ends: Pfizer-BioNTech to pay CureVac and GSK US$740m plus US sales royalties

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac US$740 ...
TipRanks on MSN1d

Pfizer’s Updated COVID-19 Vaccine Study: What Investors Need to Know

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Estimated Vaccine Effectiveness ...
MedPage Today17h

Did FDA Pick the Wrong COVID Vaccine Strain Last Season? | MedPage Today

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

Pfizer raises 2025 profit forecast as cost-cutting program gains traction

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Crain's New York Business2d

Pfizer lifts profit view as cuts offset flat sales outlook

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

Buy Pfizer Stock At $24?

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer boosts profit estimate, even as the drug giant absorbs tariffs

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...